Observational Retrospective study to characterise and assess clinical outcomes of patients receiving benralizumab after marketing approval in Spain.
18 Years +
Endpoint Classification: -
Intervention Model: -
Primary Purpose: -
Verified 01 Aug 2022 by AstraZeneca
No locations available
Patients that received at least one dose of benralizumab according to routine clinical practice